Kullich W, Pöllmann G, Zmerekar C, Klein G
Ludwig Boltzmann Institut für Rehabilitation interner Erkrankungen, Saalfelden.
Z Rheumatol. 1991 Jan-Feb;50(1):39-45.
Gastroduodenal lesions of the mucosa are known to be the most frequent side effect during therapy with non-steroidal antiinflammatory drugs (NSAIDs). We investigated the radioimmunological determination of serum-pepsinogen I as an indicator for the quality of the gastroduodenal mucosa. A good correlation was found between the endoscopy findings of 78 patients and contemporary determinations of serum-pepsinogen. Further, a follow-up of pepsinogen I was made during the treatment of 107 patients with degenerative rheumatic diseases with eight different NSAIDs. The results recommend the determination of pepsinogen I as an indicator of gastroduodenal mucosal changes under therapy with NSAIDs; this determination gives a deciding factor for the gastrolesive potency of an NSAID.
胃十二指肠黏膜病变是已知的非甾体抗炎药（NSAIDs）治疗期间最常见的副作用。我们研究了血清胃蛋白酶原I的放射免疫测定法，以此作为胃十二指肠黏膜质量的指标。在78例患者的内镜检查结果与同期血清胃蛋白酶原测定之间发现了良好的相关性。此外，在107例患有退行性风湿性疾病的患者使用8种不同的NSAIDs进行治疗期间，对胃蛋白酶原I进行了随访。结果表明，测定胃蛋白酶原I可作为NSAIDs治疗下胃十二指肠黏膜变化的指标；该测定为NSAIDs的胃损伤潜能提供了一个决定性因素。
